The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve’s interest rate cuts in September. According to GlobalData, the top 20 global biopharmaceutical companies saw a 2% rise in their combined market capitalization, reaching $4.3 trillion by the end of September, up from $4.2 trillion in June. This rebound highlights the industry’s potential for growth despite challenges earlier in the year.Bristol-Myers Sq ...